Short-Term Anticoagulation Versus Antiplatelet Therapy for Preventing

Status Recruiting

Clinical Trial Summary

The objective of the study is to compare short-term (8 weeks) anticoagulation therapy (DOAC) vs. antiplatelet therapy for the prevention of device thrombosis following transcatheter LAAC.

Clinical Trial Description

Transcatheter left atrial appendage closure (LAAC) has emerged as an alternative to anticoagulation for preventing thromboembolic events in patients with atrial fibrillation. Whereas most complications associated with LAAC have decreased over time, the occurrence of device thrombosis remains a concern, with an incidence of 1 to 17%. Antithrombotic therapy for preventing device thrombosis following LAAC has evolved empirically, with antiplatelet therapy being the most commonly prescribed treatment. However, the rates of device thrombosis post-LAAC remain relatively high and have not decreased over time despite of increasing operator/center experience and the arrival of newer generation devices. This is of particular concern if we consider that LAAC is a preventive treatment. Experimental and mechanistic studies have suggested enhanced thrombin generation (and not platelet activation) within the days-weeks following the procedure as the most important mechanism involved in device thrombosis and appropriate short-term anticoagulation therapy with DOAC should translate into a significant reduction in the rate of device thrombosis post-LAAC. Therefore, the objective of the study is to compare short-term (60 days) anticoagulation therapy (DOAC) vs. antiplatelet therapy for the prevention of device thrombosis following transcatheter LAAC. It is estimated that 350 patients will take part in the study. Update: A blinded interim analysis was performed with the analysis of clinical and TEE (central echo core lab) data from the initial 155 patients included in the study. Based on the results of the interim analysis, and considering the total number of events and the high rate (20%) of patients with either early cessation of the allocated treatment (before the 60-day TEE examination) or missing TEE at 60 days, it was decided to increase the sample size by 160 patients up to a total of 510 patients. This would ensure to include at least 350 patients with a TEE examination performed while receiving the allocated antithrombotic treatment. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03568890
Study type	Interventional
Source	Institut universitaire de cardiologie et de pneumologie de Québec, University Laval
Contact	Josep Rodes-Cabau, MD
Phone	418-656-8711
Email	josep.rodes@criucpq.ulaval.ca
Status	Recruiting
Phase	Phase 4
Start date	September 1, 2018
Completion date	September 1, 2026

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04043052` - Mobile Technologies and Post-stroke Depression	N/A
Recruiting	`NCT03869138` - Alternative Therapies for Improving Physical Function in Individuals With Stroke	N/A
Completed	`NCT04101695` - Hemodynamic Response of Anodal Transcranial Direct Current Stimulation Over the Cerebellar Hemisphere in Healthy Subjects	N/A
Completed	`NCT04034069` - Effects of Priming Intermittent Theta Burst Stimulation on Upper Limb Motor Recovery After Stroke: A Randomized Controlled Trial	N/A
Terminated	`NCT03052712` - Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies	N/A
Completed	`NCT00391378` - Cerebral Lesions and Outcome After Cardiac Surgery (CLOCS)	N/A
Recruiting	`NCT06204744` - Home-based Arm and Hand Exercise Program for Stroke: A Multisite Trial	N/A
Active, not recruiting	`NCT06043167` - Clinimetric Application of FOUR Scale as in Treatment and Rehabilitation of Patients With Acute Cerebral Injury
Active, not recruiting	`NCT04535479` - Dry Needling for Spasticity in Stroke	N/A
Completed	`NCT03985761` - Utilizing Gaming Mechanics to Optimize Telerehabilitation Adherence in Persons With Stroke	N/A
Recruiting	`NCT00859885` - International PFO Consortium	N/A
Recruiting	`NCT06034119` - Effects of Voluntary Adjustments During Walking in Participants Post-stroke	N/A
Completed	`NCT03622411` - Tablet-based Aphasia Therapy in the Chronic Phase	N/A
Completed	`NCT01662960` - Visual Feedback Therapy for Treating Individuals With Hemiparesis Following Stroke	N/A
Recruiting	`NCT05854485` - Robot-Aided Assessment and Rehabilitation of Upper Extremity Function After Stroke	N/A
Active, not recruiting	`NCT05520528` - Impact of Group Participation on Adults With Aphasia	N/A
Completed	`NCT03366129` - Blood-Brain Barrier Disruption in People With White Matter Hyperintensities Who Have Had a Stroke
Completed	`NCT05805748` - Serious Game Therapy in Neglect Patients	N/A
Completed	`NCT03281590` - Stroke and Cerebrovascular Diseases Registry
Recruiting	`NCT05993221` - Deconstructing Post Stroke Hemiparesis

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Short-Term Anticoagulation Versus Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure — ANDES

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms